Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
From outside firms

Analysis and Perspectives

Commentary and analysis from outside consulting and policy firms. Not part of Medicaid Monitor's independently scored news coverage. Each piece links back to the firm's original publication.

Avalere · Feb 6

USP Drug Classification Updates Could Shape Medicaid Formulary Decisions and Federal Pricing Models

The U.S. Pharmacopeia's 2026 Drug Classification update revises how drugs are grouped for non-Part D health plan formularies, including Medicaid managed care plans. While primarily focused on Medicare Part D guidance, these classifications influence how all health plans structure formularies and could affect drug eligibility for upcoming Medicare international reference pricing demonstrations. The annual update cycle for non-Part D classifications offers Medicaid plans more frequent opportunities to engage on drug categorization than the three-year Medicare cycle.

Read at advisory.avalerehealth.com →
Avalere · Dec 22

ACIP Reconstitution and Evolving Vaccine Recommendations May Affect Medicaid Coverage Requirements

The reconstituted Advisory Committee on Immunization Practices made changes to pediatric immunization schedules in December 2025 and signaled potential 2026 policy shifts affecting vaccines for HPV, RSV, influenza, and pregnancy-related immunizations. Because ACIP recommendations trigger mandatory Medicaid coverage without cost-sharing when published in official immunization schedules, these deliberations—and the committee's altered composition and process—carry direct implications for MCO benefit design, preventive care obligations, and pediatric and maternal health programs. The exclusion of traditional medical society liaisons from work groups may affect the clinical grounding of future recommendations that Medicaid plans must operationalize.

advisory.avalerehealth.com →
Avalere · Dec 22

340B Program Growth to $81B May Trigger Federal Reforms Affecting Medicaid DSH Hospitals

The 340B drug discount program reached $81.4 billion in 2024, with disproportionate share hospitals accounting for 78% of purchases. Many DSH hospitals also participate in Medicaid managed care, and pending federal reforms—including the 340B Rebate Model pilot and congressional bills—could reshape how these entities finance care for Medicaid beneficiaries. The program now exceeds Medicaid drug spending, making potential policy changes significant for state programs and MCOs contracting with 340B-eligible providers.

advisory.avalerehealth.com →
Avalere · Dec 19

ACIP Restructuring Creates Uncertainty for Medicaid Vaccine Coverage Policy

Major changes to the Advisory Committee on Immunization Practices—including replacement of all members and elimination of expert working groups—may affect Medicaid coverage requirements, since ACIP recommendations trigger mandatory coverage under federal law and determine which vaccines qualify for the Vaccines for Children program. The white paper examines how these structural changes could disrupt the evidence-based processes that underpin Medicaid immunization benefits and patient access protections.

advisory.avalerehealth.com →
Avalere · Dec 11

State Prescription Drug Affordability Boards Now Cover 7.8 Million Lives in Medicaid and Commercial Markets

Eight states have established Prescription Drug Affordability Review Boards (PDABs) to control drug costs, with four states (CO, MD, MN, WA) authorized to set Upper Price Limits that typically apply to both Medicaid and state-regulated commercial plans. Colorado became the first state to implement a UPL in October 2025, setting a $600 per-unit cap on Enbrel aligned with federal negotiated pricing. For Medicaid managed care plans operating in these states, PDABs represent a new layer of price regulation affecting pharmacy benefits and potentially reimbursement structures for approximately 7.8 million covered lives.

advisory.avalerehealth.com →
Avalere · Dec 3

Avalere's 2026 Outlook Flags OBBBA Medicaid Changes Amid Broader Market Shifts

Avalere's annual industry outlook report and webinar cover major 2026 healthcare trends including drug pricing reform, vaccine policy, and GLP-1 access, with one section addressing how health plans must adapt to OBBBA Medicaid provisions reshaping coverage alongside Medicare Advantage Star Ratings changes. The Medicaid angle is a minor component of a much broader multi-topic forecast aimed at pharma, payer, and market access audiences.

avalerehealth.com →
Avalere · Oct 23

Direct-to-Consumer Drug Programs May Complicate Medicaid Managed Care Pharmacy Benefits

The Trump administration is encouraging manufacturers to launch direct-to-consumer drug purchasing platforms that bypass traditional pharmacy benefit structures, with 10 manufacturers now offering such programs. While these cash-pay and potentially insurance-integrated platforms promise price transparency and patient choice, they create uncertainty for Medicaid MCOs around claims tracking, formulary management, adherence monitoring, and Stars performance measurement. The piece explores manufacturer design considerations but does not substantively address Medicaid-specific implications.

advisory.avalerehealth.com →
Avalere · Oct 20

Medicaid Vaccine Reimbursement Remains Variable Across States and Provider Types, 2025 Analysis Shows

A 50-state review finds persistent disparities in how Medicaid reimburses physician offices, pharmacies, and FQHCs for adult vaccines, with physician offices typically paid less than Medicare rates and pharmacies receiving low administration fees. While some states have modestly increased non-COVID vaccine administration rates and expanded pharmacy billing permissions, new federal fiscal constraints and potential ACIP recommendation changes may further pressure state vaccine access policies. These reimbursement structures directly affect managed care contracting strategies and network adequacy for preventive services.

advisory.avalerehealth.com →
Avalere · Sep 29

Regulatory Roadmap for Late 2025: What Federal Policy Shifts Mean for Medicaid Plans

Avalere outlines major federal health policy developments expected through the end of 2025, including Medicare Part D formulary changes, drug pricing negotiations, and ongoing PBM scrutiny under the Trump administration. While focused primarily on Medicare, the piece touches on broader regulatory trends around drug pricing and benefit management that affect Medicaid managed care operations and state policy planning. The analysis provides context for understanding how federal pharmaceutical policy changes may influence Medicaid managed care contracting and formulary strategies.

advisory.avalerehealth.com →
Avalere · Sep 24

OBBBA Legislation Imposes Work Requirements, Eligibility Restrictions, and Provider Tax Limits on Medicaid Programs

Federal legislation enacted in July 2025 introduces mandatory work requirements, accelerated eligibility redeterminations, and immigration status restrictions expected to affect 7.8 million Medicaid enrollees by 2034. The law also restricts states' use of provider taxes to finance their Medicaid programs, forcing significant changes to state funding strategies and managed care operations. MCOs will face new compliance obligations around work requirement verification, more frequent eligibility reviews, and dual market impacts as disenrolled members shift to exchange coverage.

advisory.avalerehealth.com →
Avalere · Sep 22

State and Federal PBM-Pharmacy Ownership Bans Could Reshape Medicaid Managed Care Pharmacy Networks

Avalere analyzes emerging state and federal legislation that would restrict or ban PBM ownership of pharmacies, following Arkansas's pioneering but contested prohibition. For Medicaid MCOs—which contract with PBMs for pharmacy benefits and must ensure adequate network access—these reforms could force restructuring of pharmacy relationships, potentially affecting network adequacy, pharmacy reimbursement models, and the vertical integration strategies that many health plans have pursued to control pharmacy costs.

advisory.avalerehealth.com →
Avalere · Sep 22

How Medicaid Eligibility Changes Under OBBBA May Shift Manufacturer Payer Mix and Access Strategy

Avalere examines how federal policy changes—including OBBBA Medicaid cuts, Medicare Part D redesign, and MFN pricing—are forcing pharmaceutical manufacturers to recalibrate market access strategies based on shifting payer mix across therapeutic areas. The analysis suggests Medicaid enrollment declines could push patients into commercial or uninsured coverage, affecting manufacturer uptake dynamics and requiring MCOs and state Medicaid programs to actively engage manufacturers to maintain therapeutic area prioritization. Manufacturers may need to redesign patient support programs and channel strategies as Medicaid's share of coverage for certain drugs contracts.

advisory.avalerehealth.com →
Avalere · Sep 16

Medicare Part D Data Shows Shift from Institutional to Home-Based Long-Term Care Pharmacy Services

Analysis of 2018-2022 Medicare Part D claims reveals growing pharmacy spending for beneficiaries in home and community-based settings, while nursing facility spending declined. This trend mirrors the broader shift in long-term services and supports delivery that Medicaid managed care organizations are navigating, particularly as states expand HCBS waivers and MCOs increasingly coordinate pharmacy benefits for dually eligible members receiving LTSS in non-institutional settings.

advisory.avalerehealth.com →
Avalere · Sep 3

Independent Pharmacies Face Growing Financial Pressure from Declining Medicaid Reimbursement

Independent pharmacies are struggling with financial viability driven in part by declining reimbursement rates across government payers including Medicaid, alongside Medicare and commercial plans. The analysis examines how pharmacy closures are creating access deserts that disproportionately affect vulnerable populations, with pharmacies adapting through expanded services like home delivery and vaccination programs. For Medicaid MCOs, pharmacy network adequacy and access remain critical compliance considerations as independent pharmacies face consolidation pressure.

advisory.avalerehealth.com →
Avalere · Aug 27

State AI Regulations Increasingly Target Health Plan Prior Authorization and Utilization Management

Twenty-nine states and DC have enacted laws regulating AI use in healthcare as of August 2025, with prior authorization restrictions being a primary focus that spans Medicaid, Medicare Advantage, and commercial plans. These laws often prohibit AI from serving as the sole basis for coverage denials or require licensed physicians to make final adverse determinations, directly affecting how managed care organizations structure their utilization management programs. The regulatory landscape continues to evolve with at least 10 states considering additional AI-related healthcare legislation.

advisory.avalerehealth.com →
Avalere · Aug 22

USPSTF Overhaul Threatens Evidence-Based Preventive Service Coverage Standards

Reported plans to dismiss all USPSTF members raise concerns about politicization of preventive care recommendations that underpin coverage requirements under the ACA and Medicaid. Medical societies warn that disrupting the Task Force's evidence-based process could destabilize access to screenings and preventive services including cancer detection, HIV prevention, and maternal mental health interventions. Since USPSTF recommendations trigger mandatory coverage requirements for Medicaid managed care plans, changes to the Task Force's composition and methodology could reshape preventive care obligations and plan benefits.

advisory.avalerehealth.com →
Avalere · Jul 31

Planned USPSTF Membership Overhaul Could Reshape Preventive Care Coverage Requirements for Health Plans

The administration's reported plan to dismiss all USPSTF members and reconstitute the panel could fundamentally alter preventive care coverage mandates that apply to Medicaid managed care organizations. Because ACA requirements tie no-cost preventive service coverage to USPSTF 'A' and 'B' grade recommendations, changes to the Task Force's composition and methodology could affect MCO benefit design, coverage obligations, and access to services like cancer screenings and PrEP. The move mirrors recent changes to ACIP that have already influenced vaccine policy across public programs.

advisory.avalerehealth.com →
Avalere · Jul 22

Budget Reconciliation Bill Tightens Provider Tax Rules, Threatening State Medicaid Financing Models

The One Big Beautiful Bill Act (OBBBA) introduces new restrictions on state provider taxes, a critical financing mechanism used by all states except Alaska to draw down federal Medicaid matching funds. The changes will force states to restructure how they fund Medicaid programs, with direct consequences for MCO rate-setting, provider reimbursement levels, and benefit coverage. Medicaid managed care organizations should prepare for potential state budget pressures that could impact capitation rates and contract terms as states scramble to replace lost federal matching dollars.

advisory.avalerehealth.com →
Avalere · Jul 16

State Biosimilar Substitution Laws Present Operational Challenges for Medicaid Pharmacy Programs

Avalere's updated 50-state survey documents how biosimilar substitution statutes vary across jurisdictions in authorization requirements, notification protocols, and dispensing conditions. For Medicaid managed care plans operating across multiple states, these statutory differences create compliance complexity in pharmacy benefit management, formulary design, and provider education. The report provides a reference tool for MCO pharmacy teams navigating interchangeable biosimilar policies that directly affect prior authorization workflows and member access.

advisory.avalerehealth.com →
Avalere · Jul 11

GLP-1 Coverage for Obesity Treatment Remains Limited in Medicaid Despite Growing Pipeline

Coverage of anti-obesity medications, particularly GLP-1 receptor agonists, varies significantly across payer types, with Medicaid programs showing particularly restrictive policies despite a growing pipeline of over 40 products and projected market growth to $150 billion by 2030. The analysis examines how differences between commercial, Medicare, and Medicaid coverage create access disparities, with implications for state Medicaid programs navigating budget pressures alongside federal policy efforts to expand access. Medicaid managed care plans face particular challenges balancing long-term value against immediate cost concerns as member uptake increases.

advisory.avalerehealth.com →

Get the daily briefing.